Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07458347) titled 'A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation' on March 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Kestrel Therapeutics, Inc.
Condition:
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)
KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
KRAS-mutant Colorectal Cancer (CRC)
Other KRAS-mutant Solid Tumors
Intervention:
Drug: KST-6051
Recruitment Status: Not recruiting
Phase:...